Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - AU
The Guardian - AU
National
Natasha May

Weight loss drug Wegovy approved to treat heart disease in overweight and obese Australian patients

Boxes of Wegovy move along a packaging line
Wegovy is part of the same class of drugs as Ozempic, known as GLP-1 RAs, which mimic the hormone that stimulates the digestive system, essentially telling the body it is full after eating. Photograph: Tom Little/Reuters

A weight loss drug has been approved to treat heart disease in overweight and obese patients by Australia’s medicines regulator, in what experts say is a “new frontier for the drugs”.

The Therapeutic Goods Administration (TGA) granted approval in December 2024 for semaglutide 2.4 mg, sold under the brand name Wegovy, to be used as a complementary therapy for adults with both cardiovascular disease and high body mass index, to reduce the related risk of heart attack, stroke or death.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.